Enteric gram-negative bacilli suppress Candida biofilms on Foley urinary catheters

APMIS

Volumn 122, Issue 1, 2014, Pages 47-58

  Samaranayake, Y H ^a   Bandara, H M H N ^a   Cheung, B P K ^a   Yau, J Y Y ^a   Yeung, S K W ^a   Samaranayake, L P ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Artificial urine; Bacteria; Biofilms; Candida; Catheters

Indexed keywords

GLUCOSE; LIPOPOLYSACCHARIDE;

ARTICLE; ARTIFICIAL URINE; BACILLUS; BACTERIAL COLONIZATION; BIOFILM; BROTH DILUTION; CANDIDA ALBICANS; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CULTURE MEDIUM; DUAL SPECIES BIOFILM; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FOLEY BALLOON CATHETER; FUNGUS GROWTH; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOSPECIES BIOFILM; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCANNING ELECTRON MICROSCOPY; SPECIES DIFFERENCE; URINARY CATHETER; URINE;

EID: 84891143822     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12098     Document Type: Article

References (31)

1. Niveditha S, Pramodhini S, Umadevi S, umar S, Stephen S. The isolation and the biofilm formation of uropathogens in the patients with catheter associated urinary tract infections (UTIs). J Clin Diagn Res 2012;6:1478-82.
2. Jain M, Dogra V, Mishra B, Thakur A, Loomba SP, Aradhana B. Candiduria in catheterized intensive care unit patients. Emerg Microbiol Trend 2011;54:552-5.
3. Gubbins PO, Piscitelli SC, Danziger LH. Candidal urinary tract infections: a comprehensive review of their diagnosis and management. Pharmacotherapy 1993;13:110-27.
4. Saint S, Chenoweth CE. Biofilms and catheter-associated urinary-tract infections. Infect Dis Clin North Am 2003;17:411-32.
5. Denstedt J, Wollin T, Rede G. Biomaterials used in urology: current issues of biocompatibility, infection and encrustation. J Endourol 1998;12:493-500.
6. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol 2003;11:30-6.
7. Pierce GE. Pseudomonas aeruginosa, Candida albicans, and device-related nosocomial infections: implications, trends, and potential approaches for control. J Ind Microbiol Biotechnol 2005;32:309-18.
8. Hermann C, Hermann J, Munzel U, Ruchel R. Bacterial flora accompanying Candida yeasts in clinical specimens. Mycoses 1999;42:619-27.
9. Choong S, Whitfield H. Biofilms and their role in infections in urology. BJU Int 2000;86:935-41.
10. Nickel JC, Downey JA, Costerton JW. Ultrastructural study of microbiologic colonization of urinary catheters. Urology 1989;34:284-91.
11. Geerlings SE, Meiland R, van Lith EC, Brouwer EC, Gaastra W, Hoepelman AIM. Adherence of type 1- fimbriated Escherichia coli to uroepithelial cells. Diabet Care 2002;25:1405-9.
12. Platt R, Polk BF, Murdock B, Rosner B. Risk factors for nosocomial urinary tract infection. Am J Epidemiol 1986;124:977-85.
13. McCourtie J, Douglas LJ. Relationship between cell surface composition of Candida albicans and adherence to acrylic after growth on different carbon sources. Infect Immun 1981;32:1234-41.
14. Thein ZM, Samaranayake YH, Samaranayake LP. Dietary sugars, serum and the biocide chlorhexidine digluconate modify the population and structural dynamics of mixed Candida albicans and Escherichia coli biofilms. APMIS 2007;115:1241-51.
15. Trautner BW, Hull RA, Darouiche RO. Escherichia coli 83972 inhibits catheter adherence by a broad spectrum of uropathogens. Urology 2003;61:1059-62.
16. Bandara HMHN, Yau JYY, Watt RM, Jin LJ, Samaranayake LP. Escherichia coli and its lipopolysaccharide modulate in vitro Candida biofilm formation. J Med Microbiol 2009;58:1623-31.
17. Bandara HMHN, Lam OLT, Watt RM, Jin LJ, Samaranayake LP. Bacterial lipopolysaccharides variably modulate in vitro biofilm formation of Candida species. J Med Microbiol 2010;59:1225-34.
18. Chutipongtanate S, Thongboonkerd V. Systematic comparisons of artificial urine formulas for in vitro cellular study. Anal Biochem 2010;402:110-2.
19. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard M27-A2. 2nd ednWayne, PA: National Committee for Clinical Laboratory Standards, 2002.
20. Bagshaw SM, Laupland KB. Epidemiology of intensive care unit-acquired tract infections. Curr Opin Infect Dis 2006;19:67-71.
21. Chenoweth CE, Saint S. Urinary tract infections. Infect Dis Clin North Am 2011;25:103-15.
22. Thein ZM, Samaranayake YH, Samaranayake LP. Effect of oral bacteria on growth and survival of Candida albicans biofilms. Arch Oral Biol 2006;51:672-80.
23. Bandara HMHN, Yau JYY, Watt RM, Jin LJ, Samaranayake LP. Pseudomonas aeruginosa inhibits in vitro Candida biofilm development. BMC Microbiol 2010;10:1-25.
24. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCornick T, Ghannoum MA, et al. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 2001;183:5385-94.
25. Hawser SP, Douglas LJ. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect Immun 1994;62:915-21.
26. Jin Y, Samaranayake LP, Samaranayake YH, Yip HK. Biofilm formation of Candida albicans is variably affected by saliva and dietary sugars. Arch Oral Biol 2004;49:789-98.
27. Samaranayake LP, Geddes DAM, Weetman DA, MacFarlane TW. Growth and acid production of Candida albicans in carbohydrate supplemented media. Microbios 1983;37:105-15.
28. Samaranayake LP, Hughes A, MacFarlane TW. The proteolytic potential of Candida albicans in human saliva supplemented with glucose. J Med Microbiol 1984;17:13-22.
29. Samaranayake LP, Raeside JM, MacFarlane TW. Factors affecting the phospholipase activity of Candida species in vitro. Sabouraudia 1984;22:201-7.
30. Wang X, Quinn PJ. Lipopolysaccharide: Biosynthetic pathway and structure modification. Prog Lipid Res 2010;49:97-107.
31. Darouiche R, Donovan W, Del Terzo M, Thornby J, Rudy D, Hull R. Pilot trial to bacterial interference for preventing urinary tract infection. Urology 2001;58:339-44.